EUVIMEDEUVIMED entdecken
Crossref

Design, synthesis, and in‐silico study of novel triarylethylene analogs with dual anti‐estrogenic and serotonergic activity

Tammy Mostafa, Miriam Albeir, Jannette Wober, Ashraf Abadi, Ismail Salama, Nermin S Ahmed iD

Drug Development Research · 2024

DOI: 10.1002/ddr.22127 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2024. Verfasst von Tammy Mostafa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt. Hauptthemen laut MEDLINE: Estrogen Receptor alpha, Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: Academy of Scientific Research and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Estrogen receptor is an important target in breast cancer. Serotonin receptors (5‐HT 2A and 5‐HT 2C , in particular) were investigated for a potential role in development and progression of breast cancer. Ligands that interact with estrogenic receptors influence the emotional state of females. Thus, designing selective estrogen receptor modulator (SERM) analogs with potential serotonergic activity is a plausible approach. The dual ligands can augment cytotoxic effect of SERMs, help in both physical and emotional menopausal symptom relief, enhance cognitive function and support bone health. Herein, we report triarylethylene analogs as potential candidates for treatment of breast cancer. Compound 2e showed (ERα relative β‐ galactosidase activity = 0.70), 5‐HT 2A (K i = 0.97 µM), and 5‐HT 2C (K i = 3.86 µM). It was more potent on both MCF‐7 (GI 50 = 0.27 µM) and on MDA‐MB‐231 (GI 50 = 1.86 µM) compared to tamoxifen (TAM). Compound 4e showed 40 times higher antiproliferative activity on MCF‐7 and 15 times on MDA‐MBA compared to TAM. Compound 4e had higher average potency than TAM on all nine tested cell line panels. Our in‐silico model revealed the binding interactions of compounds 2 and 2e in the three receptors; further structural modifications are suggested to optimize binding to the ERα, 5‐HT 2A , and 5‐HT 2C .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Estrogen Receptor alphaBreast NeoplasmsFemaleHumansSerotoninTamoxifenEstrogen AntagonistsSelective Estrogen Receptor ModulatorsReceptors, Estrogen

Stichwörter der Autor:innen

5-HT2A5-HT2CCYP2D6ERbreast cancermenopausetamoxifen

Substanzen

Estrogen Receptor alphaSerotoninTamoxifenEstrogen AntagonistsSelective Estrogen Receptor ModulatorsReceptors, Estrogen

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt.
  • Institute of Zoology, Faculty of Biology, Technische Universität Dresden, Dresden, Germany.
  • Department of Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt.

ORCID-Profile: Nermin S Ahmed

Förderung

  • Academy of Scientific Research and Technology

Zitieren

APA

Mostafa, T., Albeir, M., Wober, J., Abadi, A., Salama, I., & Ahmed, N. S. (2024). Design, synthesis, and in‐silico study of novel triarylethylene analogs with dual anti‐estrogenic and serotonergic activity. Drug Development Research. https://doi.org/10.1002/ddr.22127

Vancouver

Mostafa T, Albeir M, Wober J, Abadi A, Salama I, Ahmed NS. Design, synthesis, and in‐silico study of novel triarylethylene analogs with dual anti‐estrogenic and serotonergic activity. Drug Development Research. 2024. doi:10.1002/ddr.22127

BibTeX
@article{Mostafa2024,
  author = {Mostafa, Tammy and Albeir, Miriam and Wober, Jannette and Abadi, Ashraf and Salama, Ismail and Ahmed, Nermin S},
  title = {Design, synthesis, and in‐silico study of novel triarylethylene analogs with dual anti‐estrogenic and serotonergic activity},
  journal = {Drug Development Research},
  year = {2024},
  doi = {10.1002/ddr.22127}
}
Kostenlos starten →